Home > Resources > Whitepapers > ASSESSING DRUG TARGET ASSOCIATION FROM BIOLOGICAL EVIDENCES

ASSESSING DRUG TARGET ASSOCIATION FROM BIOLOGICAL EVIDENCES

December 8, 2016

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules. The subsequent identification of the molecular targets that underlie an observed phenotypic response termed target deconvolution is an essential step.

Spotlight

iPLATO Healthcare

iPLATO Healthcare is a London based innovation company dedicated to Health Tech since 2006. iPLATO’s evidence based mobile health solutions have proven to improve patient access to healthcare, to enable powerful health promotion targeted at people at risk and to support people with long term conditions.

OTHER WHITEPAPERS

Connecting materials sciences with fungal biology: a sea of possibilities

whitePaper | March 1, 2022

The Special Issue “Connecting materials science with fungal biology” celebrates recent breakthroughs in the fabrication of fungal-based materials, all of which have been made possible by the interdisciplinary and transdisciplinary collaboration of fungal biologists and biotechnologists with artists, designers, materials scientists, and architects

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.